227 related articles for article (PubMed ID: 17507091)
21. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP).
Malcovati L; Cazzola M
Hematology Am Soc Hematol Educ Program; 2015; 2015():299-307. PubMed ID: 26637737
[TBL] [Abstract][Full Text] [Related]
22. Challenges in Diagnosing Myelodysplastic Syndromes in the Era of Genetic Testing: Proceedings of the 13th Workshop of the European Bone Marrow Working Group.
Hebeda KM; Tzankov A; Boudova L; Saft L; Hasserjian RP; de Boer M; Fend F; Orazi A; Leguit R
Pathobiology; 2019; 86(1):62-75. PubMed ID: 29982244
[TBL] [Abstract][Full Text] [Related]
23. Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients.
Schroeder T; Ruf L; Bernhardt A; Hildebrandt B; Aivado M; Aul C; Gattermann N; Haas R; Germing U
Ann Oncol; 2010 Nov; 21(11):2267-2271. PubMed ID: 20439346
[TBL] [Abstract][Full Text] [Related]
24. [Myelodysplastic syndrome mimicking idiopathic thrombocytopenic purpura].
Hwang Y; Huh JW; Mun YC; Seong CM; Chung WS
Korean J Lab Med; 2010 Apr; 30(2):105-10. PubMed ID: 20445325
[TBL] [Abstract][Full Text] [Related]
25. ICUS/CCUS/CHIP: basics & beyond.
Jain M; Tripathi A
Expert Rev Hematol; 2017 Oct; 10(10):915-920. PubMed ID: 28832236
[TBL] [Abstract][Full Text] [Related]
26. Myelodysplastic syndrome in children and adolescents.
Niemeyer CM; Baumann I
Semin Hematol; 2008 Jan; 45(1):60-70. PubMed ID: 18179970
[TBL] [Abstract][Full Text] [Related]
27. ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications.
Valent P
Pathobiology; 2019; 86(1):30-38. PubMed ID: 29860246
[TBL] [Abstract][Full Text] [Related]
28. ASXL1 is a molecular predictor in idiopathic cytopenia of undetermined significance.
Shin DY; Park JK; Kim SM; Im K; Kim JA; Kim SY; Hwang SM; Yoon SS; Lee DS
Leuk Lymphoma; 2019 Mar; 60(3):756-763. PubMed ID: 30301403
[TBL] [Abstract][Full Text] [Related]
29. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
[TBL] [Abstract][Full Text] [Related]
30. Unique cytogenetic features of primary myelodysplastic syndromes in Chinese patients.
Li L; Liu XP; Nie L; Yu MH; Zhang Y; Qin TJ; Xiao ZJ
Leuk Res; 2009 Sep; 33(9):1194-8. PubMed ID: 19128829
[TBL] [Abstract][Full Text] [Related]
31. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome.
Yue G; Hao S; Fadare O; Baker S; Pozdnyakova O; Galili N; Woda BA; Raza A; Wang SA
Leuk Res; 2008 Apr; 32(4):553-8. PubMed ID: 17888511
[TBL] [Abstract][Full Text] [Related]
32. FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia.
Pinheiro RF; de Sá Moreira E; Silva MR; Alberto FL; Chauffaille Mde L
Cancer Genet Cytogenet; 2008 Jun; 183(2):89-93. PubMed ID: 18503825
[TBL] [Abstract][Full Text] [Related]
33. Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study.
Nann D; Rau A; Mahmutovic L; Steinhilber J; Meca V; Federmann B; Vogel W; Bonzheim I; Quintanilla-Martinez L; Fend F
Virchows Arch; 2023 Dec; 483(6):835-845. PubMed ID: 37610626
[TBL] [Abstract][Full Text] [Related]
34. The significance of bone marrow cell morphology and its correlation with cytogenetic features in the diagnosis of MDS-RA patients.
Liu D; Chen Z; Xue Y; Lu D; Zhou Y; Gong J; Wu W; Liang J; Ma Q; Pan J; Wu Y; Wang Y; Zhang J; Shen J
Leuk Res; 2009 Aug; 33(8):1029-38. PubMed ID: 19411106
[TBL] [Abstract][Full Text] [Related]
35. [The myelodysplastic syndrome I. Pathogenesis, clinical symptoms, diagnosis and differential diagnosis].
Hasselbalch HC; Juhl BR; Hansen PB
Ugeskr Laeger; 2002 Jan; 164(4):476-9. PubMed ID: 11838417
[TBL] [Abstract][Full Text] [Related]
36. Derivative (1)t(1;16)(p11;p11.1) in myelodysplastic syndrome: a case report and review of the literature.
Lunghi M; Casorzo L; De Paoli L; Riccomagno P; Rossi D; Gaidano G
Cancer Genet Cytogenet; 2010 Jan; 196(1):89-92. PubMed ID: 19963141
[TBL] [Abstract][Full Text] [Related]
37. Karyotypic analysis of bone marrow cells in pyodermic lesions associated with myelodysplastic syndrome.
Hamada T; Matsuura H; Oono T; Morizane S; Yamasaki O; Asagoe K; Yamamoto T; Tsuji K; Iwatsuki K
Arch Dermatol; 2008 May; 144(5):643-8. PubMed ID: 18490591
[TBL] [Abstract][Full Text] [Related]
38. [Abnormal polarization of T lymphocyte induces negative hematopoietic regulation in myelodysplastic syndromes].
Wu LY; Li X; Chang CK; Ying SX; Pu Q
Zhonghua Xue Ye Xue Za Zhi; 2007 Aug; 28(8):549-54. PubMed ID: 18078133
[TBL] [Abstract][Full Text] [Related]
39. Pregnancy in patients with myelodysplastic syndromes (MDS).
Volpicelli P; Latagliata R; Breccia M; Carmosino I; Stefanizzi C; Napoleone L; Vozella F; Levi A; Natalino F; Alimena G
Leuk Res; 2008 Oct; 32(10):1605-7. PubMed ID: 18374412
[TBL] [Abstract][Full Text] [Related]
40. [Chromosomal structural changes in patients with myelodysplastic syndrome].
Yu Y; Liu XP; Liu SH; Yu MH; Zhang Y; Xiao ZJ
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2693-7. PubMed ID: 18167247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
